OXiGENE, Inc. (OXiGENE) is a clinical-stage, biopharmaceutical company developing therapeutics primarily to treat cancer. The Company�s primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs), that disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival and also are associated with visual impairment in a number of ophthalmological diseases and conditions. ZYBRESTAT is its lead candidate. It is evaluating ZYBRESTAT in a randomized, controlled Phase II clinical trial, which it refer to as the FALCON trial, as a first-line treatment for stage IIIB/IV non-small cell lung cancer (NSCLC).The Company is pursuing development of OXi4503, a second-generation, dual-mechanism VDA, as a treatment for certain solid tumor types and for the treatment of myeloid leukemias.